Unicycive Therapeutics reports FY 2025 financial results and provides update on oxylanthanum carbonate NDA
Unicycive Therapeutics (NASDAQ:UNCY), a clinical-stage biopharmaceutical company focused on kidney disease therapies, reported its full-year 2025 financial results and provided a business update on March 30, 2026.










